STAT1 and Mendelian susceptibility to mycobacterial diseases: MSMD treatment includes identifying the gene mutation, as the treatment depends on the mutated gene and identification of the nontuberculous infection or BCGosis [48]. Additional treatment options are cytokine and interferon therapy, which will benefit in IL12B and IL12B1, and STAT1 therapy [1].